High-dose_melphalan_with_6-hydroxydopamine-purged_autologous_bone_marrow_transplantation_for_poor-risk_neuroblastoma._Long-term_results_are_presented_of_28_patients_who_were_diagnosed_with_neuroblastoma_at_more_than_12_months_of_age_and_who_received_melphalan_180_mg/m2_(n_=_6)_or_240_mg/m2_(n_=_22)_to_consolidate_remissions_of_Stage_IV_disease_or_to_control_refractory_disease._Twenty-four_patients_also_received_dianhydrogalactitol_180_to_240_mg/m2,_and_11_received_total_body_irradiation_450_to_600_cGy._Autologous_bone_marrow_transplantation_(ABMT)_was_performed_with_marrow_that_was_unpurged_(n_=_2)_or_purged_ex_vivo_(n_=_26)_with_6-hydroxydopamine_(6-OHDA)_20_micrograms/ml_plus_ascorbate_200_micrograms/ml._The_median_time_to_an_absolute_neutrophil_count_of_500/microliters_was_21_days_and_to_self-sustaining_platelet_counts_more_than_20,000/microliters,_28_days._One_patient_required_infusion_of_unpurged_reserve_marrow._Two_groups_of_patients_underwent_ABMT:_(1)_17_patients_(Group_I)_who_were_in_first_remission_a_median_of_7_months_after_diagnosis;_and_(2)_11_patients_(Group_II)_who_had_refractory_disease_or_were_in_second_remission._For_Group_I,_event-free_survival_was_29%_at_12_months_and_6%_at_24_months_post-ABMT._All_Group_II_patients_died_of_disease_or_ABMT-related_toxicity._Overall,_of_the_28_patients,_one_is_a_long-term_relapse-free_survivor;_five_died_of_ABMT-related_toxicity;_ten_patients_with_tumors_present_at_ABMT_had_progressive_disease_within_6_months_of_ABMT;_and_12_patients_with_no_measurable_disease_at_ABMT_relapsed_4_to_32_months_(median,_12)_post-ABMT._Among_the_latter,_six_relapses_involved_the_primary_site,_and_six_were_restricted_to_distant_sites._These_results--in_accord_with_the_long-term_outcome_in_other_series--suggest_that_for_neuroblastoma_high-dose_melphalan_cannot_be_relied_on_to_ablate_residual_disease_or_to_salvage_patients_with_refractory_tumors._In_addition,_the_pattern_of_relapse_in_several_patients_could_be_explained_by_infusion_of_incompletely_purged_autografts;_this_would_support_recent_laboratory_evidence_that_6-OHDA/ascorbate_is_a_suboptimal_purging_method.